Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (-)-demecolcine | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Demecolcine results in increased expression of ESYT2 mRNA | CTD | PMID:23649840 | 1-chloro-2,4-dinitrobenzene | affects binding | ISO | ESYT2 (Homo sapiens) | 6480464 | Dinitrochlorobenzene binds to ESYT2 protein | CTD | PMID:32991956 | 17beta-estradiol | decreases expression | EXP | | 6480464 | Estradiol results in decreased expression of ESYT2 mRNA | CTD | PMID:32145629 | 2,2',4,4'-Tetrabromodiphenyl ether | decreases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | 2 more ... | CTD | PMID:31675489 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ESYT2 mRNA | CTD | PMID:33387578 | 2,4,6-tribromophenol | decreases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | 2 more ... | CTD | PMID:31675489 | 3,3',5,5'-tetrabromobisphenol A | decreases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | tetrabromobisphenol A results in decreased expression of ESYT2 protein | CTD | PMID:31675489 | 4,4'-sulfonyldiphenol | multiple interactions | ISO | ESYT2 (Homo sapiens) | 6480464 | [bisphenol S co-treated with Fulvestrant] results in increased methylation of ESYT2 gene | CTD | PMID:31601247 | 4,4'-sulfonyldiphenol | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | bisphenol S results in increased expression of ESYT2 protein | CTD | PMID:34186270 | acrolein | multiple interactions | ISO | ESYT2 (Homo sapiens) | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of ESYT2 mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of ESYT2 mRNA | CTD | PMID:32699268 | acrylamide | increases expression | EXP | | 6480464 | Acrylamide results in increased expression of ESYT2 mRNA | CTD | PMID:28959563 | aflatoxin B1 | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Aflatoxin B1 results in increased expression of ESYT2 mRNA | CTD | PMID:21641981 | alpha-pinene | multiple interactions | ISO | ESYT2 (Homo sapiens) | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of ESYT2 mRNA and [Air Pollutants results in increased abundance of [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone]] which results in increased oxidation of ESYT2 mRNA | CTD | PMID:32699268 | antirheumatic drug | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Antirheumatic Agents results in increased expression of ESYT2 mRNA | CTD | PMID:24449571 | arsane | affects methylation | ISO | ESYT2 (Homo sapiens) | 6480464 | Arsenic affects the methylation of ESYT2 gene | CTD | PMID:25304211 | arsenic atom | affects methylation | ISO | ESYT2 (Homo sapiens) | 6480464 | Arsenic affects the methylation of ESYT2 gene | CTD | PMID:25304211 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | 7 more ... | CTD | PMID:20018196 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of ESYT2 mRNA | CTD | PMID:25181051 | bisphenol A | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | bisphenol A results in increased expression of ESYT2 protein | CTD | PMID:34186270 | bisphenol A | decreases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | bisphenol A results in decreased expression of ESYT2 protein | CTD | PMID:31675489 | bisphenol A | affects expression | EXP | | 6480464 | bisphenol A affects the expression of ESYT2 mRNA | CTD | PMID:32145629 | Bisphenol B | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | bisphenol B results in increased expression of ESYT2 protein | CTD | PMID:34186270 | bortezomib | decreases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Bortezomib results in decreased expression of ESYT2 mRNA | CTD | PMID:20977926 | caffeine | decreases expression | EXP | | 6480464 | Caffeine results in decreased expression of ESYT2 mRNA | CTD | PMID:20864626 | caffeine | affects phosphorylation | ISO | ESYT2 (Homo sapiens) | 6480464 | Caffeine affects the phosphorylation of ESYT2 protein | CTD | PMID:35688186 | calyculin a | increases expression | ISO | Esyt2 (Mus musculus) | 6480464 | calyculin A results in increased expression of ESYT2 mRNA | CTD | PMID:25270620 | CGP 52608 | multiple interactions | ISO | ESYT2 (Homo sapiens) | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to ESYT2 gene] | CTD | PMID:28238834 | cisplatin | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Cisplatin results in increased expression of ESYT2 mRNA | CTD | PMID:27392435 | cisplatin | multiple interactions | ISO | ESYT2 (Homo sapiens) | 6480464 | [Cisplatin co-treated with jinfukang] results in increased expression of ESYT2 mRNA | CTD | PMID:27392435 | copper(II) sulfate | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Copper Sulfate results in increased expression of ESYT2 mRNA | CTD | PMID:19549813 | coumarin | increases phosphorylation | ISO | ESYT2 (Homo sapiens) | 6480464 | coumarin results in increased phosphorylation of ESYT2 protein | CTD | PMID:35688186 | coumestrol | decreases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Coumestrol results in decreased expression of ESYT2 mRNA | CTD | PMID:19167446 | decabromodiphenyl ether | decreases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | decabromobiphenyl ether results in decreased expression of ESYT2 protein | CTD | PMID:31675489 | dibutyl phthalate | increases expression | ISO | Esyt2 (Mus musculus) | 6480464 | Dibutyl Phthalate results in increased expression of ESYT2 mRNA | CTD | PMID:21266533 | dioxygen | multiple interactions | ISO | Esyt2 (Mus musculus) | 6480464 | [sulforaphane affects the susceptibility to Oxygen] which affects the expression of ESYT2 mRNA | CTD | PMID:30529165 | dioxygen | multiple interactions | EXP | | 6480464 | [Oxygen deficiency co-treated with Blood Glucose deficiency co-treated with Particulate Matter] results in increased expression of ESYT2 mRNA | CTD | PMID:33729688 | disodium selenite | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Sodium Selenite results in increased expression of ESYT2 mRNA | CTD | PMID:18175754 | dorsomorphin | multiple interactions | ISO | ESYT2 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | doxorubicin | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Doxorubicin results in increased expression of ESYT2 mRNA | CTD | PMID:29803840 | ethyl methanesulfonate | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Ethyl Methanesulfonate results in increased expression of ESYT2 mRNA | CTD | PMID:23649840 | FR900359 | affects phosphorylation | ISO | ESYT2 (Homo sapiens) | 6480464 | FR900359 affects the phosphorylation of ESYT2 protein | CTD | PMID:37730182 | fulvestrant | multiple interactions | ISO | ESYT2 (Homo sapiens) | 6480464 | [bisphenol S co-treated with Fulvestrant] results in increased methylation of ESYT2 gene | CTD | PMID:31601247 | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of ESYT2 mRNA | CTD | PMID:33387578 | ivermectin | decreases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Ivermectin results in decreased expression of ESYT2 protein | CTD | PMID:32959892 | menadione | affects expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Vitamin K 3 affects the expression of ESYT2 mRNA | CTD | PMID:20044591 | methoxyacetic acid | decreases expression | EXP | | 6480464 | methoxyacetic acid results in decreased expression of ESYT2 mRNA | CTD | PMID:20864626 | methyl methanesulfonate | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Methyl Methanesulfonate results in increased expression of ESYT2 mRNA | CTD | PMID:23649840 | methylmercury chloride | decreases expression | EXP | | 6480464 | methylmercuric chloride results in decreased expression of ESYT2 mRNA | CTD | PMID:20864626 | methylmercury chloride | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | methylmercuric chloride results in increased expression of ESYT2 mRNA | CTD | PMID:28001369 | Monobutylphthalate | decreases expression | EXP | | 6480464 | monobutyl phthalate results in decreased expression of ESYT2 mRNA | CTD | PMID:20864626 | ozone | multiple interactions | ISO | ESYT2 (Homo sapiens) | 6480464 | [Acrolein co-treated with methacrylaldehyde co-treated with alpha-pinene co-treated with Ozone] results in increased oxidation of ESYT2 mRNA more ... | CTD | PMID:32699268 | phenylmercury acetate | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Phenylmercuric Acetate results in increased expression of ESYT2 mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | ESYT2 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESYT2 mRNA | CTD | PMID:27188386 | potassium dichromate | decreases expression | ISO | Esyt2 (Mus musculus) | 6480464 | Potassium Dichromate results in decreased expression of ESYT2 mRNA | CTD | PMID:23608068 | SB 431542 | multiple interactions | ISO | ESYT2 (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | sulforaphane | multiple interactions | ISO | Esyt2 (Mus musculus) | 6480464 | [sulforaphane affects the susceptibility to Oxygen] which affects the expression of ESYT2 mRNA | CTD | PMID:30529165 | sunitinib | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Sunitinib results in increased expression of ESYT2 mRNA | CTD | PMID:31533062 | temozolomide | decreases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Temozolomide results in decreased expression of ESYT2 mRNA | CTD | PMID:31758290 | thioacetamide | increases expression | EXP | | 6480464 | Thioacetamide results in increased expression of ESYT2 mRNA | CTD | PMID:34492290 | trichostatin A | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | trichostatin A results in increased expression of ESYT2 mRNA | CTD | PMID:24935251 and PMID:26272509 | trichostatin A | multiple interactions | ISO | ESYT2 (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESYT2 mRNA | CTD | PMID:27188386 | trovafloxacin | decreases expression | ISO | Esyt2 (Mus musculus) | 6480464 | trovafloxacin results in decreased expression of ESYT2 mRNA | CTD | PMID:35537566 | valproic acid | multiple interactions | ISO | ESYT2 (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESYT2 mRNA | CTD | PMID:27188386 | valproic acid | increases expression | ISO | ESYT2 (Homo sapiens) | 6480464 | Valproic Acid results in increased expression of ESYT2 mRNA | CTD | PMID:23179753 more ... | zinc atom | multiple interactions | ISO | ESYT2 (Homo sapiens) | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of ESYT2 mRNA | CTD | PMID:18593933 | zinc(0) | multiple interactions | ISO | ESYT2 (Homo sapiens) | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of ESYT2 mRNA | CTD | PMID:18593933 | |